Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ranok Starts Trials of BRD4 Protein Degradation Therapy for Solid Tumors

publication date: Aug 24, 2022

Ranok Therapeutics, a Boston-Hangzhou company started US clinical trials of a novel therapy for solid tumor cancers or diffuse large B-cell lymphoma. Ranok develops drug candidates based on its novel approach to protein degradation. The Phase I/II trial will test safety and tolerability of RNK05047, the first therapy based on Ranok's proprietary CHAMP™ technology and the first BRD4 protein degrader to start clinical trials. One year ago, Ranok raised $40 million in a B round from China investors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital